Soleno Therapeutics (SLNO) Amortization of Deferred Charges (2025 - 2026)
Soleno Therapeutics' (SLNO) quarterly Amortization of Deferred Charges came in at $8000.0 in Q1 2026, little changed year-on-year from $8000.0 in Q1 2025, and down 11.11% on a QoQ basis from $9000.0 in Q4 2025.
Soleno Therapeutics (SLNO) Amortization of Deferred Charges (2025 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has 2 years of Amortization of Deferred Charges data on file, last reported at $8000.0 in Q1 2026.
- On a quarterly basis, Amortization of Deferred Charges changed 0.0% year-over-year to $8000.0 in Q1 2026; TTM through Mar 2026 was $35000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $35000.0, changed N/A from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $8000.0, down from $9000.0 in the prior quarter.
- Over the last five years, Amortization of Deferred Charges for SLNO reached as high as $9000.0 in Q2 2025 and fell as low as $8000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.85 Bn | 467.06 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.04 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.28 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.47 Bn | 959.66 Mn |
| 10 | Soleno Therapeutics | 874.25 Mn | 618.67 Mn | 93.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8,000.00 |
| Mar 31, 2026 | 8,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Sep 30, 2025 | 9,000.00 |
| Sep 30, 2025 | 9,000.00 |
| Jun 30, 2025 | 9,000.00 |
| Jun 30, 2025 | 9,000.00 |
| Mar 31, 2025 | 8,000.00 |
| Mar 31, 2025 | 8,000.00 |